Dawn Fallik
Freelance Writer at Freelance
University of Delaware professor. Medical and science writer. Here for SQL, kayaking, yoga and all the coffee.
Articles
-
1 month ago |
journals.lww.com | Dawn Fallik
Tolebrutinib, a brain-penetrant Bruton tyrosine (BTK) inhibitor, significantly slowed disability progression in multiple sclerosis, according to research from two different phase 3 trials presented at the AAN Annual Meeting in San Diego.
-
1 month ago |
journals.lww.com | Dawn Fallik
Article In BriefTwo studies, published simultaneously with presentations at the International Stroke Conference, found that endovascular thrombectomy did not benefit patients with a medium-vessel occlusion. Still, independent experts and the authors of the two studies agreed that the findings may have been limited by the older age of the patients as well as higher procedural risks and challenges in reaching smaller vessels.
-
2 months ago |
journals.lww.com | Dawn Fallik
Two new studies, released simultaneously in February during the International Stroke Conference in Los Angeles, found that endovascular thrombectomy treatment (EVT) of strokes did not benefit, and in some cases, increased negative outcomes in patients with a medium-vessel occlusion (MeVO). The findings led to strong warnings that practitioners should reconsider EVT in patients falling under those parameters, as it is not yet evidence-based care. The findings, which were published Feb.
-
Feb 6, 2025 |
journals.lww.com | Dawn Fallik
Article In BriefThree neurologists share their personal brushes with danger as wildfires raged through and ravaged neighborhoods and structures across Los Angeles. One week after wildfires exploded across Southern California, ravaging entire neighborhoods and thousands of structures, neurologists in affected areas told Neurology Today that everyone had pulled together to support patients in crisis as well as colleagues and staff who had to evacuate.
-
Feb 6, 2025 |
journals.lww.com | Dawn Fallik
Article In BriefSleep neurologists who were interviewed by Neurology Today were generally supportive of the FDA approval of the weight-loss drug tirzepatide for obesity-related obstructive sleep apnea, as it would help patients lose weight and become more focused on a healthy diet and exercise routine. Some expressed concerns about managing expectations about the need for CPAP machines, the blood work monitoring required, and the costs of the drug.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 2K
- Tweets
- 2K
- DMs Open
- No
RT @CovidSolidarit1: If I had a friend with Long Covid (and I didn’t have it myself) I think I’d Google it extensively to find out what the…
RT @amandalitman: Elmo’s LinkedIn update has me 😫😫😫 https://t.co/mSJnw5k3Xz
RT @ChrisMurphyCT: I'm live on the Senate floor talking about how Trump is canceling billions of dollars in funding for kids' mental health…
